- Home
- RLAY vs ECPG Comparison
RLAY vs ECPG Comparison
Compare RLAY & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- ECPG
- Stock Information
- Founded
- RLAY 2015
- ECPG 1998
- Country
- RLAY United States
- ECPG United States
- Employees
- RLAY N/A
- ECPG N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- ECPG Finance Companies
- Sector
- RLAY Health Care
- ECPG Finance
- Exchange
- RLAY Nasdaq
- ECPG Nasdaq
- Market Cap
- RLAY 803.4M
- ECPG 905.2M
- IPO Year
- RLAY 2020
- ECPG 1999
- Fundamental
- Price
- RLAY $5.48
- ECPG $41.31
- Analyst Decision
- RLAY Strong Buy
- ECPG Strong Buy
- Analyst Count
- RLAY 8
- ECPG 3
- Target Price
- RLAY $17.25
- ECPG $62.67
- AVG Volume (30 Days)
- RLAY 1.6M
- ECPG 330.2K
- Earning Date
- RLAY 11-05-2025
- ECPG 11-05-2025
- Dividend Yield
- RLAY N/A
- ECPG N/A
- EPS Growth
- RLAY N/A
- ECPG N/A
- EPS
- RLAY N/A
- ECPG N/A
- Revenue
- RLAY $8,355,000.00
- ECPG $1,467,587,000.00
- Revenue This Year
- RLAY $27.33
- ECPG $27.55
- Revenue Next Year
- RLAY $8.87
- ECPG $5.84
- P/E Ratio
- RLAY N/A
- ECPG N/A
- Revenue Growth
- RLAY N/A
- ECPG 15.50
- 52 Week Low
- RLAY $1.78
- ECPG $26.45
- 52 Week High
- RLAY $7.07
- ECPG $51.77
- Technical
- Relative Strength Index (RSI)
- RLAY 75.63
- ECPG 41.77
- Support Level
- RLAY $5.17
- ECPG $40.28
- Resistance Level
- RLAY $5.42
- ECPG $44.40
- Average True Range (ATR)
- RLAY 0.29
- ECPG 1.41
- MACD
- RLAY 0.08
- ECPG -0.57
- Stochastic Oscillator
- RLAY 95.97
- ECPG 16.12
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.